A client is starting hormonal therapy with tamoxifen to lower the risk for breast cancer. What information needs to be explained by the nurse regarding the action of this drug?

A. It blocks the release of luteinizing hormone: Tamoxifen does not primarily act on the hypothalamic-pituitary axis or directly inhibit luteinizing hormone. This mechanism is more characteristic of drugs used for ovulation suppression or fertility regulation, not selective estrogen receptor modulators (SERMs) like tamoxifen. B. It interferes with cancer cell division: While tamoxifen may indirectly reduce cancer cell proliferation, its primary mechanism is not a general interference with cell division. Cytotoxic chemotherapy agents act by directly disrupting mitosis, which differs from the targeted receptor-based action of tamoxifen. C. It selectively blocks estrogen in the breast: Tamoxifen is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors in breast tissue, preventing estrogen from stimulating growth of estrogen receptor–positive breast cancer cells. This targeted antagonistic action reduces the risk of recurrence and development of breast cancer while allowing estrogen activity in other tissues, such as bone. D. It inhibits DNA synthesis in rapidly dividing cells: This mechanism is characteristic of antimetabolite chemotherapy drugs (e.g., methotrexate) rather than tamoxifen. Tamoxifen’s effect is receptor-mediated rather than a direct cytotoxic effect on DNA synthesis, making this explanation inaccurate for hormonal therapy education.